CY1114306T1 - Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας - Google Patents

Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας

Info

Publication number
CY1114306T1
CY1114306T1 CY20131100753T CY131100753T CY1114306T1 CY 1114306 T1 CY1114306 T1 CY 1114306T1 CY 20131100753 T CY20131100753 T CY 20131100753T CY 131100753 T CY131100753 T CY 131100753T CY 1114306 T1 CY1114306 T1 CY 1114306T1
Authority
CY
Cyprus
Prior art keywords
anagrelide
thrombocytalaria
individual
therapeutic treatment
new composition
Prior art date
Application number
CY20131100753T
Other languages
English (en)
Inventor
Rudolf Widmann
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of CY1114306T1 publication Critical patent/CY1114306T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά νέα σκευάσματα αναγρελίδης που έχουν ως αποτέλεσμα μη άμεση αποδέσμευση της δραστικής ουσίας αναγρελίδης. Οι εφευρέτες απέδειξαν ότι οι φαρμακευτικές συνθέσεις που περιλαμβάνουν σωματίδια αναγρελίδης, όπου τουλάχιστον 90% των προαναφερόμενων σωματιδίων είναι μικρότερα από 10μm, σε συνδυασμό με μονοϋδρική λακτόζη παρέχουν σκεύασμα με χαρακτηριστικά μειωμένης αποδέσμευσης όταν χορηγούνται σε ασθενή. Προαιρετικά, η φαρμακευτική σύνθεση μπορεί επιπλέον να περιέχει ποβιδόνη, κροσποβιδόνη, μικροκρυσταλλική κυτταρίνη ή/και στεατικό μαγνήσιο.
CY20131100753T 2008-12-05 2013-09-02 Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας CY1114306T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0070708U AT10562U3 (de) 2008-12-05 2008-12-05 Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
EP09764826.5A EP2367539B1 (en) 2008-12-05 2009-12-04 Novel composition for treatment of essential thrombocythemia

Publications (1)

Publication Number Publication Date
CY1114306T1 true CY1114306T1 (el) 2016-08-31

Family

ID=40550008

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100753T CY1114306T1 (el) 2008-12-05 2013-09-02 Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας

Country Status (20)

Country Link
EP (1) EP2367539B1 (el)
KR (1) KR101631728B1 (el)
CN (1) CN102307572B (el)
AT (1) AT10562U3 (el)
AU (1) AU2009324043B2 (el)
CY (1) CY1114306T1 (el)
DK (1) DK2367539T3 (el)
EA (1) EA022715B1 (el)
ES (1) ES2426232T3 (el)
HK (1) HK1158957A1 (el)
HR (1) HRP20130647T1 (el)
IL (1) IL213198A (el)
MY (1) MY155660A (el)
PL (1) PL2367539T3 (el)
PT (1) PT2367539E (el)
SG (1) SG171979A1 (el)
SI (1) SI2367539T1 (el)
UA (1) UA106361C2 (el)
WO (1) WO2010063824A1 (el)
ZA (1) ZA201103409B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794237C (en) * 2010-03-25 2017-09-26 Aop Orphan Pharmaceuticals Ag Novel composition for treatment of essential thrombocythemia
DK2915526T3 (da) 2014-03-07 2021-09-06 Galenicum Health S L U Farmaceutiske sammensætninger, der omfatter anagrelid
AU2015370666B2 (en) * 2014-12-22 2020-09-03 Arovella Therapeutics Limited Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2022060309A1 (en) * 2020-09-18 2022-03-24 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Long-term stable anagrelid capsule composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
BRPI0418800A (pt) * 2004-05-05 2007-10-16 Celgene Corp métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
KR20080002939A (ko) * 2005-04-12 2008-01-04 엘란 파마 인터내셔널 리미티드 나노입자형 퀴나졸린 유도체 제제
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties
US20100056493A1 (en) * 2007-01-25 2010-03-04 Rajesh Jain Modified release pharmaceutical composition and a process of making the same

Also Published As

Publication number Publication date
ZA201103409B (en) 2012-07-25
AU2009324043A1 (en) 2010-06-10
WO2010063824A1 (en) 2010-06-10
EA022715B1 (ru) 2016-02-29
CN102307572B (zh) 2015-04-08
ES2426232T3 (es) 2013-10-22
KR101631728B1 (ko) 2016-06-17
CN102307572A (zh) 2012-01-04
PL2367539T3 (pl) 2013-10-31
KR20110106280A (ko) 2011-09-28
HRP20130647T1 (en) 2013-08-31
UA106361C2 (ru) 2014-08-26
MY155660A (en) 2015-11-13
DK2367539T3 (da) 2013-08-26
PT2367539E (pt) 2013-09-09
EA201170583A1 (ru) 2011-12-30
HK1158957A1 (en) 2012-07-27
AU2009324043B2 (en) 2016-02-25
SI2367539T1 (sl) 2013-09-30
AT10562U3 (de) 2010-01-15
IL213198A (en) 2015-09-24
AT10562U2 (de) 2009-06-15
SG171979A1 (en) 2011-07-28
EP2367539A1 (en) 2011-09-28
EP2367539B1 (en) 2013-06-05
IL213198A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CY1124852T1 (el) Φαρμακευτικες συνθεσεις 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλ) κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλπυριδιν-2-υλ)βενζοϊκου οξεος και χορηγηση αυτων
CY1118232T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
CY1111446T1 (el) Συνθεσεις περιλαμβανουσες κρυσταλλικη trans- (+/-)-δελτα-9-τετραϋδροκανναβινολη
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
NO20081844L (no) Terapeutiske forbindelser
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
ATE536172T1 (de) Ezetimibzusammensetzungen
DE602008003404D1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
CY1114306T1 (el) Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
BRPI0808377B8 (pt) composto, composição e uso de um composto